RenovaCare, Inc. today announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants”) to purchase…
RenovaCare, Inc. today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct offering and common stock purchase warrants in a concurrent private placement…
RenovaCare, Inc. has announced that its approach to isolating a patient’s own stem cells for subsequent spray onto burns and wounds has been validated by researchers in ‘Differentiation’, a leading peer-reviewed scientific publication. According to their findings, the methodology, which has been…
RenovaCare highlighted an analysis of treatment results on a variety of wide-area and severe burn injuries published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The treatment method, which involved isolating and spraying the patient’s own skin stem cells on the burn wounds…
Thanks to your support, 2016 was an incredible year for us and our CellMist™ and SkinGun™ technologies for spraying a patient’s own stem cells on to wounds and burns. We closed the year emboldened by the issuance of an important new patent…
RenovaCare, Inc., announced that the company has bolstered its patent portfolio with the issuance of a United States patent for its novel SkinGun™ device. The United States Patent and Trademark Office has granted an additional 30-month extension for the patent, providing protection beyond the year 2035.
RenovaCare, Inc., announced the appointment of Roger Esteban-Vives, Ph.D. as Director of Cell Sciences.
*RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the company’s planned or filed submissions to the U.S. Food and Drug Administration, if any, will be accepted or cleared by the FDA. About RenovaCare RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell…
RenovaCare, Inc., today announced positive spray test results demonstrating that its novel SkinGun™ technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist™ and SkinGun™ technologies* for spraying fluids containing a patient’s own stem cells onto burns and wounds for rapid scar-free healing.
